|
|
News Breaks | | | | February 24, 2013 | | 13:55 EDT |  | NVS | Novartis reports omalizumab improves CIU symptoms
Results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria, CIU, referred to as chronic spontaneous urticaria, CSU, outside the United States, who remained symptomatic despite treatment with approved antihistamine doses. The data were published in the New England Journal of Medicine. Omalizumab is not indicated for CIU. The primary endpoint was measured using a 21-point scale known as a weekly Itch Severity Score. The study met its primary endpoint, showing that omalizumab given at doses of 150 mg and 300 mg every four weeks led to significant improvement from baseline at Week 12 in the mean weekly ISS from baseline (approximately 14 in all treatment groups) by 8.1 (p=0.001) and 9.8 (p<0.001), respectively, compared to a 5.1 improvement in patients on placebo. The omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo for the primary endpoint. All eight pre-specified secondary endpoints in the ASTERIA II trial were met for the 150 mg and 300 mg doses, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy. | |
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 21, 2013 | | 07:44 EDT |  | NVS | Sachs Associates to host a forum
 Subscribe for More Information | | | 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information | | | May 20, 2013 | | 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. | | | May 17, 2013 | | 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information | | | May 16, 2013 | | 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information | | | May 15, 2013 | | 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information | | | May 10, 2013 | | 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information | |
|
|
|
|
|
|
